CorMedix Inc. (CRMD) research

CorMedix Inc.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$7.78
As of

CorMedix Inc. (CRMD): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-13.

As of . Source: SEC EDGAR filings for CRMD. Method and limitations.

SHARE THIS CARD

Share the CRMD intelligence card

A branded snapshot of CRMD: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion CRMD intelligence card preview
Post to X
LIVE TERMINAL

See CRMD live in the terminal

Track CRMD's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live CRMD terminal, free

Active signals for CRMD

FREE, NO ACCOUNT

Every signal on CRMD, as it fires

You are seeing 5 of 21 signals recorded on CRMD since 2026-05-26.

The five above all landed on 2026-09-06. The other 16 were recorded on 5 other days. 15 of the 21 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in CRMD (2026Q2)

Manager / securityMarket value% portfolioQoQ
D. E. Shaw & Co., Inc.CUSIP 21900C308 · 2026Q2$1.3M0.00%,
CITADEL ADVISORS LLCCUSIP 21900C308 · 2026Q2$444K0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 21900C308 · 2026Q2$321K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, CRMD

CRMD against its peers

CRMD's operating margin of 48.2% ranks in the 96th percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.

MetricCRMDPeer medianPercentilen
Revenue FY312M USD4.6M USD9715
Gross margin88.5%n/an/a1
Operating margin48.2%-550.3%9611
Net margin52.3%-240.1%9611
Return on equity40.2%-47.0%9819
P / E3.8xn/an/a0

Peers (20): STTK, ALLO, VALN, PHAT, CBIO, ALT, EPRX, PRME, CTMX, NGNE, OCS, MNPR, AURA, VSTM, ARVN, RGNX, TECX, CAPR, OVID, SGMT. Left out: SCTX (no annual filing), AGMB (no annual filing), BLSM (no annual filing), DRUG (period gap), EIKN (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (CRMD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more CRMD signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CRMDand get the insider, 13F, options, and confluence read in one view.

Open the live CRMD terminal, free